A New Frontier in Immune Tolerance: The IL-2–TGFβ Surrogate Agonist

The immune system's ability to distinguish between self and non-self is fundamental to health, but when this balance fails, autoimmune diseases, allergies, and chronic inflammation can result. Traditional approaches to modulating immune responses often involve broad immunosuppression, which can leave patients vulnerable to infections. A groundbreaking study published in Nature reveals a sophisticated new approach: an interleukin-2–TGFβ surrogate agonist that selectively induces immune tolerance by generating specialized regulatory T cells. This innovative technology represents a significant advancement in precision immunology, offering targeted therapeutic potential without compromising overall immune function.

The Science Behind Immune Tolerance

Immune tolerance is maintained by specialized cells called regulatory T cells (Treg cells), which prevent excessive immune responses against the body's own tissues and harmless environmental antigens. There are two main types: thymic Treg cells (tTreg cells) that develop in the thymus to enforce self-tolerance, and peripherally induced Treg cells (pTreg cells) that arise from mature CD4+ T cells in response to specific antigens. While both TGFβ and IL-2 are known to promote pTreg cell development in laboratory settings, their combined therapeutic potential in vivo has remained largely unexplored until now.

The challenge has been that TGFβ, while potent, has problematic side effects including promoting fibrosis and tumor growth, and has unfavorable pharmacokinetic properties. IL-2, on the other hand, has been engineered to preferentially target Treg cells but primarily expands existing tTreg cells rather than generating new antigen-specific pTreg cells. The new research addresses these limitations through an ingenious molecular design that combines the benefits of both cytokines while minimizing their drawbacks.

Designing the IL-2–TGFβ Surrogate Agonist

The research team created a bi-specific molecule called TGM1–IL-2 by fusing interleukin-2 to a low-affinity TGFβ mimic agonist derived from a helminth parasite. This design creates an "AND-gated" co-agonist that simultaneously activates both IL-2–STAT5 and TGFβ–SMAD2/3 signaling pathways specifically in T cells expressing IL-2 receptors. The molecule functions as a single-chain fusion protein with mouse serum albumin added to improve its in vivo half-life.

Three variants were tested with different IL-2 receptor binding affinities: wild-type IL-2, IL-2(N88D) with reduced affinity for preferential Treg stimulation, and IL-2(H9) with enhanced affinity for broader immune cell activation. The low-affinity TGFβ mimic component enables the fusion proteins to co-activate SMAD2/3 signaling in IL-2 receptor-expressing cells while providing tunable STAT5 activation potency. This precise targeting mechanism represents a significant advancement in cytokine engineering for therapeutic applications.

Mechanism of Action and Cellular Effects

The TGM1–IL-2 surrogate agonist demonstrates remarkable specificity in its cellular effects. Signaling assays in primary mouse CD4+ T cells showed that the molecule induces phosphorylated STAT5 (pSTAT5) in CD25+ cells at levels comparable to their respective IL-2 counterparts, while markedly enhancing SMAD2/3 activation. The dose-response curve for phosphorylated SMAD2/3 (pSMAD2/3) shifted leftward by approximately 2.5 logs compared to low-affinity TGM1 alone, reflecting increased apparent TGFβ receptor-binding affinity driven by IL-2–IL-2 receptor engagement.

In vitro differentiation assays using mouse naive CD4+ T cells revealed that TGM1–IL-2 significantly enhances FOXP3+ pTreg cell generation, shifting the dose-response curve leftward by about 2 logs compared to either low-affinity TGM1 alone or the combination of separate TGM1 and IL-2 molecules. The induced pTreg cells demonstrated potent suppressive function in vitro, effectively inhibiting naive T cell proliferation and activation. These findings establish the molecule's ability to efficiently drive highly functional pTreg cell induction under controlled conditions.

In Vivo Efficacy and Therapeutic Potential

The most compelling evidence comes from in vivo studies using mouse models of immune-mediated diseases. In OVA-immunized mice, TGM1–IL-2 variants drove robust FOXP3+ pTreg cell induction, reaching up to approximately 80% conversion of antigen-specific T cells in mesenteric lymph nodes, inguinal lymph nodes, and spleen. These induced pTreg cells displayed an effector-like phenotype with high RORγt expression, enabling efficient migration and tissue-specific function.

In therapeutic models, pretreatment with TGM1–IL-2(WT) markedly protected against allergic airway inflammation compared to controls, as evidenced by lower lung inflammation scores, reduced serum IgE levels, and decreased immune cell infiltration. Similarly, in experimental autoimmune encephalomyelitis (EAE) models of neuroinflammation, the treatment robustly drove antigen-specific T cells to differentiate into functional pTreg cells and provided significant protection against disease development, with 9 out of 11 mice remaining EAE-free compared to nearly all control mice developing disease.

Clinical Implications and Future Directions

The development of this IL-2–TGFβ surrogate agonist represents a paradigm shift in approaches to immune tolerance induction. Unlike current Treg cell therapies that mainly expand polyclonal tTreg cells using IL-2 agents—resulting in short-lived expansion and lack of antigen specificity—this technology generates antigen-specific pTreg cells that offer targeted control of pathological immune responses while preserving overall immune function. This precision approach could significantly reduce the risk of systemic immunosuppression associated with current therapies.

The research also provides important insights into the molecular requirements for optimal pTreg cell differentiation, expansion, and functional maturation. Studies using a signaling-deficient variant (TGM1–IL-2(DN)) demonstrated that IL-2 signaling is required for optimal pTreg cell expansion and suppressive function in vivo, highlighting the importance of coordinated TGFβ and IL-2 pathway activation. Single-cell RNA sequencing analysis further revealed that the induced pTreg cells exhibit transcriptional profiles enriched for effector and colonic Treg signatures, with coordinated activation of both pathways driving a distinct pTreg program while suppressing alternative CD4+ T cell fates.

While the current molecule uses a helminth-derived TGFβ mimic component, the researchers note that more human-tolerable drug-like TGFβ mimics could be developed from tandem variable heavy chain (VHH) domains, which have been shown to act as surrogate cytokine agonists. This opens avenues for further optimization and clinical translation. The technology's ability to induce durable, functional pTreg cells that persist through multiple antigen re-challenges suggests it may provide sufficient inductive signals without requiring additional co-factors typically needed for pTreg stability.

Conclusion

The IL-2–TGFβ surrogate agonist represents a significant advancement in the field of immunology and therapeutic development. By harnessing the synergistic effects of two key cytokine pathways through precise molecular engineering, researchers have created a tool that can selectively induce antigen-specific immune tolerance in vivo. The technology's demonstrated efficacy in suppressing both allergic inflammation and autoimmune neuroinflammation in preclinical models suggests broad therapeutic potential across diverse immune-mediated conditions.

As research progresses toward clinical applications, this approach could revolutionize treatment strategies for autoimmune diseases, allergies, transplantation, and other conditions requiring immune modulation. The ability to generate targeted, durable immune tolerance while minimizing systemic side effects addresses a critical unmet need in immunology and offers hope for more effective and safer treatments for millions of patients worldwide. The study not only presents a promising therapeutic candidate but also advances our fundamental understanding of immune regulation and the molecular requirements for establishing lasting tolerance.